Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

AACR 2016 /
Targeted therapy shows continued promise in patients whose tumours had NTRK gene fusions

16th - 20th Apr 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 29.04.16
Views: 1848

Dr David Hong - University of Texas MD Anderson Cancer Center, Houston, USA

Dr David Hong speaks with ecancertv at AACR 2016 with updated results targeting TRK fusions with LOXO101.

NTRK, normally associated with the sense of touch, can fuse and become oncogenic in a variety of tumour histologies.

LOXO101 is described as the first selective inhibitor of TRKa, b and c, compared to the more generalised entrectinib, which Dr Hong reports as assuring greater specificity and thus lower offtarget effects.

A Phase II trial is ongoing.

For more on Trk fusions, you can watch an interview with Dr Alexander Drilon about a entrectinib, a TRK targeted therapy.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation